Pulmatrix, Inc. (NASDAQ:PULM) Sees Significant Increase in Short Interest

Pulmatrix, Inc. (NASDAQ:PULM) was the recipient of a large growth in short interest during the month of August. As of August 31st, there was short interest totaling 20,198 shares, a growth of 384.2% from the August 15th total of 4,171 shares. Based on an average daily volume of 12,801 shares, the short-interest ratio is presently 1.6 days. Approximately 0.6% of the shares of the stock are sold short.

Pulmatrix Price Performance

NASDAQ:PULM traded down $0.03 during mid-day trading on Friday, reaching $1.44. The company’s stock had a trading volume of 5,674 shares, compared to its average volume of 41,472. The company’s fifty day simple moving average is $1.60 and its two-hundred day simple moving average is $1.61. Pulmatrix has a twelve month low of $1.16 and a twelve month high of $5.50. The stock has a market cap of $5.24 million, a P/E ratio of -1.30 and a beta of 1.90.

Pulmatrix (NASDAQ:PULM) last posted its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($2.00) by $1.71.

Hedge Funds Weigh In On Pulmatrix

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in Pulmatrix during the second quarter valued at approximately $93,000. DRW Securities LLC acquired a new stake in shares of Pulmatrix in the fourth quarter worth $46,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Pulmatrix during the 3rd quarter valued at $52,000. Institutional investors and hedge funds own 11.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut Pulmatrix from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 14th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Pulmatrix currently has a consensus rating of “Sell”.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).